Aviko Radiopharmaceuticals
Initial Transaction Details
Transaction Date
September 2021
Purpose of Financing
Venture
Stage of Company
Seed/Startup
Structure of Financing
Equity
Aviko Radiopharmaceuticals is a privately held biotechnology company developing medicines to unlock the potential of boron neutron capture therapy (BNCT) to treat a wide variety of cancers. Aviko’s innovative compounds are designed to improve the efficacy of BNCT by targeting and delivering boron to cancer cells with precision. Together with their partners, Aviko is advancing BNCT as a safe, efficacious and convenient treatment modality for patients. Founded by Deerfield Management.
Website